Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment

Acta Neurol Scand. 2002 Nov;106(5):253-7. doi: 10.1034/j.1600-0404.2002.01336.x.

Abstract

Forty-seven patients with the late borrelial manifestation acrodermatitis chronica atrophicans (ACA) and with objective neurological and/or neurophysiological findings were followed up after antibiotic treatment with dermatological, serological, neurological and neurophysiological controls. Despite a good therapeutic effect on ACA lesions, specific antibody values and symptoms of irritative nerve lesions, the objective neurological and neurophysiological findings of nerve deficit remained unchanged. There was no progress of neuropathy findings during the follow-up time. Our interpretation of the results is that the remaining neuropathy signs after treatment of ACA are neurological sequelae and not manifestations of persisting Borrelia infection.

Publication types

  • Clinical Trial

MeSH terms

  • Acrodermatitis / complications*
  • Acrodermatitis / drug therapy*
  • Acrodermatitis / physiopathology
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Borrelia burgdorferi / drug effects
  • Borrelia burgdorferi / pathogenicity*
  • Cefuroxime / therapeutic use*
  • Doxycycline / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Lyme Disease / complications*
  • Lyme Disease / drug therapy*
  • Lyme Disease / physiopathology
  • Male
  • Middle Aged
  • Penicillins / therapeutic use*
  • Peripheral Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / etiology*
  • Peripheral Nervous System Diseases / physiopathology
  • Prospective Studies
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Penicillins
  • Doxycycline
  • Cefuroxime